Citadel Advisors
IPHA

Citadel Advisors’s Innate Pharma IPHA Stock Holding History

Citadel Advisors’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,042
Closed -$39.1K – 13347
2025
Q3 		$39.1K Sell
20,042
-6,575
-25% -$13.2K ﹤0.01% 12305
2025
Q2 		$46.6K Buy
26,617
+2,350
+10% +$4.77K ﹤0.01% 11804
2025
Q1 		$43.2K Buy
24,267
+12,414
+105% +$24.2K ﹤0.01% 12460
2024
Q4 		$21.9K Sell
11,853
-9,414
-44% -$17.7K ﹤0.01% 13121
2024
Q3 		$48.7K Sell
21,267
-2,260
-10% -$4.99K ﹤0.01% 11945
2024
Q2 		$45.6K Buy
+23,527
New +$59.1K ﹤0.01% 11867
2023
Q3 		– Sell
-13,281
Closed -$41.7K – 14673
2023
Q2 		$41.7K Buy
+13,281
New +$40.8K ﹤0.01% 12025
2021
Q2 		– Sell
-25,250
Closed -$109K – 14025
2021
Q1 		$109K Buy
+25,250
New +$113K ﹤0.01% 12400

Other funds holding IPHA

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's IPHA Position: Q4 2025 in Review

Citadel Advisors sold out of Innate Pharma (IPHA) in Q4 2025, closing a stake of 20,042 shares — an estimated $39.1K sold.

Citadel Advisors first reported a position in IPHA in Q1 2021 and held it in 8 quarters. The position peaked at $109K in Q1 2021. 11 funds tracked by Wall St. Rank hold IPHA as of Q4 2025.

  • Citadel Advisors reported no remaining Innate Pharma position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 20,042 Innate Pharma shares in Q4 2025, an estimated $39.1K.
  • Citadel Advisors first reported a position in Innate Pharma in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Innate Pharma position peaked at $109K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.